SCHEMBL2085404

SCHEMBL2085404

CCCCCNC(=O)N(C)c1cccc(-c2ccc(CCC(=O)O)cc2C)c1

nearest known ligand 0.43

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 8/20 0.43
PTGS2 P35354 2/20 0.42
FFAR4 Q5NUL3 3/20 0.42
FAAH O00519 1/20 0.41
HPGD P15428 1/20 0.41
LTB4R2 Q9NPC1 1/20 0.41
S1PR1 P21453 2/20 0.39
RARB P10826 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2085413 0.99 PTGS2 (0.44) FFAR1PTGS2FFAR4FAAHHPGD
SCHEMBL2085208 0.91 PTGS2 (0.44) PTGS2FAAHHPGDLTB4R2S1PR1
SCHEMBL2085985 0.90 PTGS2 (0.43) PTGS2FAAHHPGDLTB4R2RARB
SCHEMBL2085832 0.90 PTGS2 (0.43) FFAR1PTGS2FAAHHPGDLTB4R2
SCHEMBL2083519 0.89 PTGS2 (0.54) FFAR1PTGS2FAAHHPGDRARB
SCHEMBL12935167 0.88 FAAH (0.40) FFAR1PTGS2FFAR4FAAHHPGD
SCHEMBL12935173 0.88 FAAH (0.40) FFAR1PTGS2FFAR4FAAHHPGD
SCHEMBL5169595 0.88 FAAH (0.40) FFAR1PTGS2FAAHHPGDLTB4R2
SCHEMBL12935185 0.87 FAAH (0.41) FFAR1PTGS2FFAR4FAAHHPGD
SCHEMBL12935196 0.87 PTGS2 (0.41) PTGS2FAAHHPGDLTB4R2S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863332-B2 Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-04 US claimed
EP-1781297-B1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-10-15 EP claimed
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-13 US claimed
EP-1781297-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP claimed
WO-2006018326-A1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO claimed
US-7863332-B2 Biaromatic compound activators of PPARγ receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-01-04 US disclosed
EP-1781297-B1 NOVEL BIAROMATIC COMPOUNDS THAT ACTIVATE PPAR TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-10-15 EP disclosed
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213336-A1 Biaromatic compound activators of ppargamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD FFAR1 13/4885PTGS2 625/4885FFAR4 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.